A randomized, double-blind, placebo-controlled, phase III clinical study evaluating regorafenib in combination with best supportive care versus placebo in combination with best supportive care in patients with progressive metastatic and/or inoperable gastrointestinal mesenchymal tumors (GIST) who had been treated with at least imatinib and sunitinib . GIST is the most common primary gastrointestinal mesenchymal tumor. The estimated incidence of GIST based on the general population is 11 to 20 patients/million people/year. In patients with metastatic and/or non-surgically resectable GIST, molecularly targeted therapies have been the focus of treatment approaches over the past decade. The 2 most starring drugs are: gleevec and sotanex, which play an important role in the first- and second-line treatment of GIST, respectively. Imatinib mesylate (Glivec, Glivec) is a selective TKI for KIT, PDGFR, ABL kinase and chimeric BCR-ABL, and is the first TKI approved by the Drug Regulatory Agency for the treatment of patients with KIT-positive unresectable and/or metastatic GIST and for adjuvant therapy after resection of limited primary tumors. Sunitinib (Sotan, Sotan) Sutent) is an oral multi-targeted receptor TKI targeting all 3 subtypes of the vascular endothelial growth factor receptor (VEGFR), KIT, PDGFR and several other factor receptors, and is approved for the treatment of patients with unresectable and/or metastatic malignant GIST who have failed treatment with imatinib mesylate due to drug resistance or intolerance. Now there is a new problem, many GIST patients who have received both lines of treatment have disease progression, so what to do, this is the most headache in the international treatment of GIST, before we face such patients also helpless, now maybe we can have a new option: Regorafenib. It is a novel diphenylurea targeting angiogenic, mesenchymal and oncogenic kinases oral multi-kinase inhibitor. It is currently in the clinical research phase in our department. This drug is considered to be possibly the third new drug approved for gastrointestinal mesenchymal tumors after Gleevec and Sotan, and if you are eligible, there is hope that you will receive this latest drug in parallel with other GIST tumor patients internationally.